Â鶹×îгöÆ·

Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation - Â鶹×îгöÆ· - Outstanding Awards (Details)

v3.22.4
Stock-Based Compensation - Â鶹×îгöÆ· - Outstanding Awards (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Additional disclosures Ìý Ìý Ìý
Total unrecognized compensation cost related to unvested equity awards $ 31 Ìý Ìý
Weighted average period of recognition related to unvested equity awards (in years) 1 year 4 months 24 days Ìý Ìý
Options, exercises in period, total intrinsic value $ 84 $ 144 $ 8
Restricted Stock and Restricted Stock Units Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Equity instruments other than options, vested in period, fair value $ 16 $ 13 $ 45
Â鶹×îгöÆ· SiriusXM Group Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Common stock reserved for issuance 6,900 Ìý Ìý
Â鶹×îгöÆ· SiriusXM Group | Common Class A and B Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at end of period 0 Ìý Ìý
Â鶹×îгöÆ· SiriusXM Group | Series C Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at beginning of period 7,369 Ìý Ìý
Granted 254 Ìý Ìý
Exercised (760) Ìý Ìý
Forfeited/Cancelled (1) Ìý Ìý
Outstanding at end of period 6,862 7,369 Ìý
Exercisable at end of period 4,883 Ìý Ìý
WAEP Ìý Ìý Ìý
Outstanding at beginning of period $ 38.79 Ìý Ìý
Granted 44.29 Ìý Ìý
Exercised 31.22 Ìý Ìý
Forfeited/Cancelled 31.87 Ìý Ìý
Outstanding at end of period 39.83 $ 38.79 Ìý
Exercisable at end of period $ 37.89 Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Weighted average remaining life, outstanding 2 years 9 months 18 days Ìý Ìý
Weighted average remaining life, exercisable 2 years 2 months 12 days Ìý Ìý
Aggregate intrinsic value, outstanding $ 14 Ìý Ìý
Aggregate intrinsic value, exercisable $ 14 Ìý Ìý
Â鶹×îгöÆ· SiriusXM Group | Restricted Stock and Restricted Stock Units Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Equity instruments other than options, nonvested, number 73 Ìý Ìý
Restricted stock weighted average grant-date fair value $ 41.28 Ìý Ìý
Formula One Group Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Common stock reserved for issuance 7,100 Ìý Ìý
Formula One Group | Common Class A and B Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at end of period 0 Ìý Ìý
Formula One Group | Series C Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at beginning of period 9,114 Ìý Ìý
Granted 301 Ìý Ìý
Exercised (2,329) Ìý Ìý
Outstanding at end of period 7,086 9,114 Ìý
Exercisable at end of period 5,625 Ìý Ìý
WAEP Ìý Ìý Ìý
Outstanding at beginning of period $ 34.38 Ìý Ìý
Granted 57.92 Ìý Ìý
Exercised 31.96 Ìý Ìý
Outstanding at end of period 36.18 $ 34.38 Ìý
Exercisable at end of period $ 34.19 Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Weighted average remaining life, outstanding 3 years 9 months 18 days Ìý Ìý
Weighted average remaining life, exercisable 3 years 6 months Ìý Ìý
Aggregate intrinsic value, outstanding $ 167 Ìý Ìý
Aggregate intrinsic value, exercisable $ 144 Ìý Ìý
Formula One Group | Restricted Stock and Restricted Stock Units Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Equity instruments other than options, nonvested, number 74 Ìý Ìý
Restricted stock weighted average grant-date fair value $ 55.34 Ìý Ìý
Braves Group Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Common stock reserved for issuance 3,100 Ìý Ìý
Braves Group | Common Class A and B Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at end of period 0 Ìý Ìý
Braves Group | Series C Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at beginning of period 3,125 Ìý Ìý
Granted 105 Ìý Ìý
Exercised (122) Ìý Ìý
Outstanding at end of period 3,108 3,125 Ìý
Exercisable at end of period 1,493 Ìý Ìý
WAEP Ìý Ìý Ìý
Outstanding at beginning of period $ 25.86 Ìý Ìý
Granted 26.20 Ìý Ìý
Exercised 18.12 Ìý Ìý
Outstanding at end of period 26.17 $ 25.86 Ìý
Exercisable at end of period $ 24.92 Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Weighted average remaining life, outstanding 4 years 4 months 24 days Ìý Ìý
Weighted average remaining life, exercisable 3 years 10 months 24 days Ìý Ìý
Aggregate intrinsic value, outstanding $ 19 Ìý Ìý
Aggregate intrinsic value, exercisable $ 11 Ìý Ìý
Braves Group | Restricted Stock and Restricted Stock Units Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Equity instruments other than options, nonvested, number 178 Ìý Ìý
Restricted stock weighted average grant-date fair value $ 31.55 Ìý Ìý